Gene therapy developer CRISPR Therapeutics AG (CRSP) is navigating some regulatory and commercial dynamics. Its flagship gene ...

Pfizer (NYSE:PFE) is a global pharmaceutical giant that has long been a cornerstone of medical innovation and today boasts a ...

We expect investors to focus on the sales numbers of CRISPR Therapeutics’ CRSP sole-marketed product, Casgevy, and other ...

We expect Vertex Pharmaceuticals Incorporated VRTX to surpass expectations when it reports first-quarter 2025 results on May ...

The FDA has lost no time in approving Vertex Pharma and CRISPR Therapeutics pioneering gene-editing therapy Casgevy for its second use, approving the drug for transfusion-dependent beta ...

Investing in the specialist workforce and overcoming access barriers is essential to successful delivery of this therapy in the NHS, write Jessie Enakhumhe and Yasmin Sheikh Casgevy, or exagamglogene ...

Its first approved product, Casgevy, was developed in collaboration with narrow-moat Vertex Pharmaceuticals to treat transfusion-dependent beta-thalassemia (TDT) and sickle-cell disease (SCD).

Gene editing company ToolGen “seeks fair licensing agreement” for alleged infringement by rival | High-value sickle cell ...

Vertex and partner CRISPR Therapeutics’ CRSP one-shot gene therapy, Casgevy, was approved in late 2023/early 2024 for two blood disorders — sickle cell disease and transfusion-dependent beta ...

We expect investors to focus on the sales numbers of CRISPR Therapeutics’ CRSP sole-marketed product, Casgevy, and other pipeline updates when it reports first-quarter 2025 results. The Zacks ...